465 related articles for article (PubMed ID: 24623375)
1. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C.
Kazankov K; Barrera F; Møller HJ; Bibby BM; Vilstrup H; George J; Grønbaek H
Hepatology; 2014 Aug; 60(2):521-30. PubMed ID: 24623375
[TBL] [Abstract][Full Text] [Related]
2. Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection.
Lidofsky A; Holmes JA; Feeney ER; Kruger AJ; Salloum S; Zheng H; Seguin IS; Altinbas A; Masia R; Corey KE; Gustafson JL; Schaefer EA; Hunt PW; Deeks S; Somsouk M; Chew KW; Chung RT; Alatrakchi N
J Infect Dis; 2018 Sep; 218(9):1394-1403. PubMed ID: 29868909
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus.
Dultz G; Gerber L; Farnik H; Berger A; Vermehren J; Pleli T; Zeuzem S; Piiper A; Kronenberger B; Waidmann O
J Viral Hepat; 2015 Apr; 22(4):427-32. PubMed ID: 25181653
[TBL] [Abstract][Full Text] [Related]
4. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment.
Laursen TL; Wong GL; Kazankov K; Sandahl T; Møller HJ; Hamilton-Dutoit S; George J; Chan HL; Grønbaek H
J Gastroenterol Hepatol; 2018 Feb; 33(2):484-491. PubMed ID: 28618015
[TBL] [Abstract][Full Text] [Related]
5. Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology.
Lund Laursen T; Brøckner Siggard C; Kazankov K; Damgaard Sandahl T; Møller HJ; Ong A; Douglas MW; George J; Tarp B; Hagelskjaer Kristensen L; Lund Laursen A; Hiramatsu A; Nakahara T; Chayama K; Grønbaek H
Scand J Gastroenterol; 2018 Aug; 53(8):986-993. PubMed ID: 29987961
[TBL] [Abstract][Full Text] [Related]
6. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease.
Kazankov K; Barrera F; Møller HJ; Rosso C; Bugianesi E; David E; Younes R; Esmaili S; Eslam M; McLeod D; Bibby BM; Vilstrup H; George J; Grønbaek H
Liver Int; 2016 Oct; 36(10):1549-57. PubMed ID: 27102725
[TBL] [Abstract][Full Text] [Related]
7. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
Kazankov K; Tordjman J; Møller HJ; Vilstrup H; Poitou C; Bedossa P; Bouillot JL; Clement K; Grønbaek H
J Gastroenterol Hepatol; 2015 Aug; 30(8):1293-300. PubMed ID: 25772748
[TBL] [Abstract][Full Text] [Related]
8. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
[TBL] [Abstract][Full Text] [Related]
9. Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis.
Baeten D; Møller HJ; Delanghe J; Veys EM; Moestrup SK; De Keyser F
Arthritis Rheum; 2004 May; 50(5):1611-23. PubMed ID: 15146432
[TBL] [Abstract][Full Text] [Related]
10. Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study.
Andersen ES; Rødgaard-Hansen S; Moessner B; Christensen PB; Møller HJ; Weis N
Eur J Clin Microbiol Infect Dis; 2014 Jan; 33(1):117-22. PubMed ID: 24424890
[TBL] [Abstract][Full Text] [Related]
11. Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure.
Hiraoka A; Horiike N; Akbar SM; Michitaka K; Matsuyama T; Onji M
J Gastroenterol; 2005 Jan; 40(1):52-6. PubMed ID: 15692789
[TBL] [Abstract][Full Text] [Related]
12. The macrophage activation marker CD163 is associated with IL28B genotype and hepatic inflammation in chronic hepatitis C virus infected patients.
Dultz G; Gerber L; Zeuzem S; Sarrazin C; Waidmann O
J Viral Hepat; 2016 Apr; 23(4):267-73. PubMed ID: 26554542
[TBL] [Abstract][Full Text] [Related]
13. Soluble CD163 and interleukin-6 are increased in aqueous humour from patients with endothelial rejection of corneal grafts.
Funding M; Vorum H; Nexø E; Moestrup SK; Ehlers N; Møller HJ
Acta Ophthalmol Scand; 2005 Apr; 83(2):234-9. PubMed ID: 15799739
[TBL] [Abstract][Full Text] [Related]
14. CD14
Zhao SX; Li WC; Fu N; Kong LB; Zhang QS; Han F; Ren WG; Cui P; Du JH; Wang BY; Zhang YG; Wang RQ; Kong L; Nan YM
Exp Ther Med; 2020 Dec; 20(6):228. PubMed ID: 33149783
[TBL] [Abstract][Full Text] [Related]
15. Soluble CD163 is associated with noninvasive measures of liver fibrosis in hepatitis C virus- and hepatitis C virus/human immunodeficiency virus-infected women.
Kuniholm MH; Hanna DB; Landay AL; Kaplan RC; Ley K
Hepatology; 2015 Feb; 61(2):734-5. PubMed ID: 25044447
[No Abstract] [Full Text] [Related]
16. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis.
Grønbaek H; Sandahl TD; Mortensen C; Vilstrup H; Møller HJ; Møller S
Aliment Pharmacol Ther; 2012 Jul; 36(2):173-80. PubMed ID: 22591184
[TBL] [Abstract][Full Text] [Related]
17. Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD.
Axelsson J; Møller HJ; Witasp A; Qureshi AR; Carrero JJ; Heimbürger O; Bárány P; Alvestrand A; Lindholm B; Moestrup SK; Stenvinkel P
Am J Kidney Dis; 2006 Dec; 48(6):916-25. PubMed ID: 17162146
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma.
Waidmann O; Köberle V; Bettinger D; Trojan J; Zeuzem S; Schultheiß M; Kronenberger B; Piiper A
J Hepatol; 2013 Oct; 59(4):769-79. PubMed ID: 23792028
[TBL] [Abstract][Full Text] [Related]
19. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S
J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782
[TBL] [Abstract][Full Text] [Related]
20. Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease.
Rødgaard-Hansen S; St George A; Kazankov K; Bauman A; George J; Grønbæk H; Jon Møller H
Scand J Clin Lab Invest; 2017 Nov; 77(7):498-504. PubMed ID: 28715286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]